AMPEL BioSolutions

AMPEL BioSolutions is a private, commercial-stage biotech leveraging a proprietary AI-driven genomic platform to bring precision medicine to complex autoimmune diseases. The company has launched its first laboratory-developed test (LDT), LuGENE® for lupus, and has a pipeline of planned tests in dermatology and wellness. AMPEL's competitive edge stems from its disease-agnostic platform and what it claims is the world's largest curated database of autoimmune patient gene expression profiles, which fuels its machine learning models. The company is positioned at the intersection of diagnostics, AI, and immunology, aiming to reduce uncertainty in clinical decision-making for dynamic chronic conditions.

AMPEL Genomic Platform (AGP®): A disease-agnostic platform integrating RNA analytics, bioinformatics, and deep machine learning/AI. It analyzes gene expression from blood or biopsy to create a patient's 'Genomic Fingerprint,' powered by a proprietary database of >20,000 autoimmune patient profiles.

AMPEL competes in the broad precision medicine and AI diagnostics space, where companies like Tempus and Foundation Medicine focus more on oncology. Direct competitors in autoimmune RNA-based diagnostics are emerging but limited. AMPEL's claimed differentiators are its exclusive, large autoimmune-specific database and its disease-agnostic platform designed for dynamic disease management rather than static diagnosis.